Improvement in systemic inflammation after selective inhibition of STAT3 or STAT5 in the secondary HLH model. (A) Immunoblot analysis of phosphorylated STAT3 and STAT5 in liver tissue. (B) Experimental design for the secondary HLH model in which WT C57BL/6N mice were injected with CpG on days 0, 2, 4, 7, and 9 and with analysis conducted on day 10 after the first injection. (C) Liver and spleen weight normalized to body weight. (D) Changes in WBC counts, Hb concentration, PLT counts, and the frequencies of neutrophils, monocytes, and lymphocytes. (E) Quantified serum levels of IL-6, TNF-α, MCP-1, IFN-γ, and CXCL9. (F) Liver mRNA expression of Il6, Tnfa, Il18, and Cxcl9. The data points represent individual mice from a single experiment. (G) Immunoblot of the NET marker citH3 in the liver. (H) Densitometric analysis of citH3/GAPDH in panel G. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Veh, vehicle.